Breaking News Instant updates and real-time market news.

DBX

Dropbox

$34.40

2.86 (9.07%)

17:23
08/09/18
08/09
17:23
08/09/18
17:23

Dropbox sees FY18 revenue $1.366B-$1.372B, consensus $1.36B

Sees FY18 non-GAAP operating margin 9.5%-10.5%; free cash flow $340M-$350M.

  • 09

    Aug

  • 04

    Sep

DBX Dropbox
$34.40

2.86 (9.07%)

05/11/18
ADAM
05/11/18
NO CHANGE
Target $36
ADAM
Buy
Dropbox weakness a buying opportunity, says Canaccord
Canaccord analyst Richard Davis noted Dropbox shares sold off following its Q1 earnings release but he said he would be an "aggressive buyer" of the shares using the weakness as a buying opportunity. He noted the company delivered upside on every metric and made progress on customer additions, ARPU, and product innovation. Davis reiterated his Buy rating and raised his price target to $36 from $35 on Dropbox shares.
05/17/18
DBAB
05/17/18
NO CHANGE
DBAB
Buy
Google changes unlikely to impact Dropbox, says Deutsche Bank
Dropbox (DBX) rival Google (GOOG, GOOGL) this week announced some changes to its consumer-based cloud storage service, Deutsche Bank analyst Karl Keirstead tells investors in a research note. The analyst notes that Google is moving all paid Google Drive consumer subscribers to a newly named Google One service, which includes added storage capacity options, "expert assistance" and the ability to add family members. Google also cut the price of its 2TB capacity plan in half, to $10 from $20 per month, Keirstead adds. He does not see these changes materially impacting Dropbox and keeps a Buy rating on the shares.
08/01/18
JEFF
08/01/18
UPGRADE
Target $32
JEFF
Buy
Dropbox upgraded to Buy from Hold at Jefferies
Jefferies analyst John DiFucci upgraded Dropbox to Buy with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation." The stock is down 16% over the past week "on no material change," DiFucci tells investors in a research note. He continues to view Dropbox's "attractive, sustainable model as unique in software."
08/01/18
08/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JEFFERIES UPGRADES DROPBOX TO BUY: Jefferies analyst John DiFucci upgraded Dropbox (DBX) to Buy from Hold with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation," he stated. Dropbox is up 4.7% in late morning trading. JEFFERIES UPGRADES PAPA JOHN'S: Jefferies analyst Alexander Slagle upgraded Papa John's (PZZA) to Buy from Hold and raised his price target for the shares to $58 from $52. The stock, down 50% from highs, now reflects the likelihood that fundamentals will get worse before improving, Slagle said. After reviewing the company's potential path to recovery and possible strategic actions that could create shareholder value, the analyst has a bull case of $75 per share. He thinks this outweighs the bear case, or downside risk, of $35 per share. SAREPTA UPGRADED AFTER PULLBACK: Morgan Stanley analyst Matthew Harrison upgraded Sarepta Therapeutics (SRPT) to Overweight from Equal Weight, noting that the stock has given up much of the gains it saw when its initial DMD gene therapy data was announced. He sees the pullback as an opportunity to own the stock near pre-DMD gene therapy levels without taking the binary risk. He doesn't think a major bear case has emerged on the prospects for the company's DMD gene therapy program and he sees major catalysts in the second half of this year that he believes the market is missing. Harrison has a $163 price target on Sarepta shares. PIPER CUTS SHOPIFY TO NEUTRAL: Piper Jaffray analyst Michael Olson downgraded Shopify (SHOP) to Neutral from Overweight and lowered his price target to $145 from $155, saying that Shopify's Q2 was "good, but not good enough" with monthly recurring revenue below investor expectations. While Olson said Shopify is performing well, he believes their performance is mostly reflected in the stock's current valuation. PIPER RECOMMENDS BIOGEN AFTER MANAGEMENT MEETING: After hosting investor meetings with Biogen (BIIB) investor relations this week, Piper Jaffray analyst Christopher Raymond came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond said. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on Biogen. He kept an Overweight rating on shares with a $400 price target.

TODAY'S FREE FLY STORIES

RMD

ResMed

07:38
12/10/18
12/10
07:38
12/10/18
07:38
Upgrade
ResMed rating change  »

ResMed upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$109.97

-2.38 (-2.12%)

07:38
12/10/18
12/10
07:38
12/10/18
07:38
Upgrade
ResMed rating change  »

ResMed upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

07:38
12/10/18
12/10
07:38
12/10/18
07:38
Recommendations
Gilead analyst commentary  »

Gilead landing Daniel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$109.97

-2.38 (-2.12%)

07:38
12/10/18
12/10
07:38
12/10/18
07:38
Upgrade
ResMed rating change  »

ResMed upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGEN

Compugen

$3.30

-0.16 (-4.62%)

07:37
12/10/18
12/10
07:37
12/10/18
07:37
Conference/Events
Compugen management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MNLO

Menlo Therapeutics

$5.69

0.13 (2.34%)

07:37
12/10/18
12/10
07:37
12/10/18
07:37
Conference/Events
Menlo Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

EBIX

Ebix

$47.17

0.24 (0.51%)

07:35
12/10/18
12/10
07:35
12/10/18
07:35
Hot Stocks
Ebix division to provide foreign exchange services at India airport »

Ebix announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

NRG

NRG Energy

$40.53

-0.01 (-0.02%)

07:35
12/10/18
12/10
07:35
12/10/18
07:35
Recommendations
NRG Energy analyst commentary  »

NRG Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROX

Tronox

$7.30

-0.4 (-5.19%)

07:35
12/10/18
12/10
07:35
12/10/18
07:35
Hot Stocks
Tronox confirms decision by FTC judge regarding pending Cristal acquisition »

Tronox confirmed receipt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCMP

Cabot Microelectronics

$96.77

-4.7 (-4.63%)

07:35
12/10/18
12/10
07:35
12/10/18
07:35
Conference/Events
Cabot Microelectronics management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

AAPL

Apple

$168.37

-6.37 (-3.65%)

, BAC

Bank of America

$25.43

-0.86 (-3.27%)

07:35
12/10/18
12/10
07:35
12/10/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$168.37

-6.37 (-3.65%)

BAC

Bank of America

$25.43

-0.86 (-3.27%)

ATVI

Activision Blizzard

$47.21

-0.94 (-1.95%)

ET

Energy Transfer LP

$14.26

0.03 (0.21%)

DE

Deere

$147.27

-7.01 (-4.54%)

QD

Qudian

$4.97

-0.04 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

COP

ConocoPhillips

$65.93

-0.68 (-1.02%)

07:33
12/10/18
12/10
07:33
12/10/18
07:33
Hot Stocks
ConocoPhillips sets FY19 CapEx budget of $6.1B »

ConocoPhillips has set a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SKY

Skyline

$17.59

-0.67 (-3.67%)

07:33
12/10/18
12/10
07:33
12/10/18
07:33
Conference/Events
Skyline management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

PG

Procter & Gamble

$92.45

-1.08 (-1.15%)

07:33
12/10/18
12/10
07:33
12/10/18
07:33
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SMLP

Summit Midstream

$12.72

-0.05 (-0.39%)

07:33
12/10/18
12/10
07:33
12/10/18
07:33
Hot Stocks
Summit Midstream CFO Matthew Harrison to depart »

Summit Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$65.93

-0.68 (-1.02%)

07:32
12/10/18
12/10
07:32
12/10/18
07:32
Hot Stocks
ConocoPhillips sees 2019 production of 1,300-1,350 MBOED »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ONTX

Onconova

$3.47

-0.29 (-7.71%)

07:32
12/10/18
12/10
07:32
12/10/18
07:32
Hot Stocks
Onconova names Avi Oler as VP, corporate development and general counsel »

Onconova Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MITK

Mitek Systems

$8.98

-0.12 (-1.32%)

07:32
12/10/18
12/10
07:32
12/10/18
07:32
Hot Stocks
ASG Technologies increases offer to $11.50 per share to acquire Mitek Systems »

ASG Technologies made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$6.00

-0.1 (-1.64%)

07:31
12/10/18
12/10
07:31
12/10/18
07:31
Upgrade
Synchronoss rating change  »

Synchronoss upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$26.99

-0.62 (-2.25%)

, SPLK

Splunk

$105.70

-5.43 (-4.89%)

07:30
12/10/18
12/10
07:30
12/10/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GPS

Gap

$26.99

-0.62 (-2.25%)

SPLK

Splunk

$105.70

-5.43 (-4.89%)

ON

ON Semiconductor

$17.37

-0.91 (-4.98%)

AEO

American Eagle

$18.96

-0.81 (-4.10%)

EQT

EQT Corporation

$18.42

0.41 (2.28%)

NYT

New York Times

$25.11

-0.8 (-3.09%)

TER

Teradyne

$32.60

-1.18 (-3.49%)

USAT

USA Technologies

$4.22

-0.18 (-4.09%)

KAR

KAR Auction

$51.04

-3.17 (-5.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 09

    Jan

  • 03

    Mar

  • 08

    May

AUY

Yamana Gold

$2.26

0.075 (3.43%)

07:29
12/10/18
12/10
07:29
12/10/18
07:29
Downgrade
Yamana Gold rating change  »

Yamana Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCM

R1 RCM

$8.71

-0.31 (-3.44%)

07:29
12/10/18
12/10
07:29
12/10/18
07:29
Initiation
R1 RCM initiated  »

R1 RCM initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$137.42

-2.14 (-1.53%)

07:26
12/10/18
12/10
07:26
12/10/18
07:26
Recommendations
Facebook analyst commentary  »

Facebook valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$10.82

0.2 (1.88%)

07:26
12/10/18
12/10
07:26
12/10/18
07:26
Hot Stocks
Voyager Therapeutics doses first patient in RESTORE-1 trial »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$27.56

-1.85 (-6.29%)

07:26
12/10/18
12/10
07:26
12/10/18
07:26
Conference/Events
Vanda Pharmaceuticals to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.